Traders should monitor uptake following the full market launch at SIR 2026 in April; increased clinical validation could accelerate adoption, but no immediate revenue catalyst is present.
Price Chart
Executive Summary
Microbot Medical announced the publication of its ACCESS-PVI multicenter feasibility study in the Journal of Vascular and Interventional Radiology (JVIR), a premier peer-reviewed journal. This publication validates the clinical data for its LIBERTY Endovascular Robotic System, which received FDA clearance in September 2025 and is set for full market release in April 2026.
Key Facts
- LIBERTY System received FDA clearance in September 2025 for peripheral endovascular procedures.
- Study titled 'In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions' published in JVIR, a top-tier peer-reviewed journal.
- The ACCESS-PVI study was completed in 2025 and previously presented at SIR 2025; peer review adds credibility to clinical results.
- Full market release of LIBERTY planned for April 2026 at the SIR conference.
- LIBERTY is the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
Financial Impact
No direct financial impact disclosed; long-term commercial adoption may improve with peer-reviewed validation.
Risk Factors
- Commercial execution risk — limited market release has not yet demonstrated widespread adoption.
- Forward-looking statements about growth and adoption are speculative and subject to regulatory and market risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261223 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.9570 | awaiting T+1 | — | $1.03 (+7.63%) |
Oct 23, 2026 4d ago | 8-K | $0.9739 $0.9417 | ▼ −3.31% | ▼ −4.02% | $1.03 (+5.76%) |
Oct 20, 2026 7d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $1.03 (+8.71%) |
Oct 6, 2026 21d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $1.03 (−3.74%) |
Oct 6, 2026 21d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $1.03 (−3.74%) |
Sep 28, 2026 29d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $1.03 (−17.60%) |
Aug 11, 2026 11w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $1.03 (−38.69%) |
Jul 21, 2026 14w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $1.03 (−42.78%) |
Jul 7, 2026 16w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $1.03 (−45.79%) |
Jun 30, 2026 17w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $1.03 (−47.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers